GlassScriptPhysician profile
David W Chang
NPI 1285732172
$5,608.75
in general payments reported to CMS, 2019-2025
10 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $769 · 2021: $121 · 2022: $429 · 2023: $2,981 · 2024: $474 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,500 · Travel and Lodging: $820 · Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,500.00 |
| Travel and Lodging | $819.80 |
| Food and Beverage | $560.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $3,319.80 | 2023-2024 | |
| Baxter Healthcare | $768.75 | 2020 | |
| Abbott Laboratories | $363.79 | 2022-2025 | Aveir |
| Tepha INC | $274.64 | 2019 | |
| Galderma Laboratories, L.P. | $193.42 | 2022 | |
| Access Pro Medical, LLC | $154.76 | 2025 | Matriderm |
| Integra Lifesciences Corporation | $142.72 | 2022 | |
| Scanlan International INC | $135.41 | 2019 | |
| Kerecis Limited | $134.55 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Acelrx Pharmaceuticals, INC. | $120.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.